Texas Permanent School Fund increased its stake in Cambrex Corp. (NYSE:CBM) by 0.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,489 shares of the company’s stock after buying an additional 36 shares during the period. Texas Permanent School Fund owned 0.08% of Cambrex Corp. worth $1,089,000 as of its most recent filing with the SEC.
A number of other hedge funds also recently bought and sold shares of the company. Great West Life Assurance Co. Can raised its stake in Cambrex Corp. by 4.6% in the third quarter. Great West Life Assurance Co. Can now owns 43,354 shares of the company’s stock valued at $1,927,000 after buying an additional 1,907 shares in the last quarter. American Capital Management Inc. bought a new stake in Cambrex Corp. during the third quarter valued at about $15,110,000. Boston Advisors LLC raised its stake in Cambrex Corp. by 7.8% in the third quarter. Boston Advisors LLC now owns 12,147 shares of the company’s stock valued at $540,000 after buying an additional 875 shares in the last quarter. Nationwide Fund Advisors raised its stake in Cambrex Corp. by 10.1% in the third quarter. Nationwide Fund Advisors now owns 221,619 shares of the company’s stock valued at $9,853,000 after buying an additional 20,345 shares in the last quarter. Finally, Genesee Valley Trust Co. bought a new stake in Cambrex Corp. during the third quarter valued at about $247,000. Institutional investors own 99.56% of the company’s stock.
Shares of Cambrex Corp. (NYSE:CBM) traded up 0.50% during mid-day trading on Friday, hitting $50.05. 74,072 shares of the stock traded hands. Cambrex Corp. has a one year low of $29.50 and a one year high of $59.41. The firm has a market capitalization of $1.61 billion, a P/E ratio of 26.43 and a beta of 1.81. The company’s 50 day moving average is $45.16 and its 200 day moving average is $47.85.
Cambrex Corp. (NYSE:CBM) last posted its quarterly earnings results on Friday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.06. Cambrex Corp. had a net margin of 13.24% and a return on equity of 24.11%. The firm had revenue of $99.90 million for the quarter, compared to analyst estimates of $96.07 million. During the same period in the prior year, the firm posted $0.40 earnings per share. The company’s quarterly revenue was up 8.2% compared to the same quarter last year. On average, equities analysts expect that Cambrex Corp. will post $2.70 EPS for the current fiscal year.
Several analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $53.00 price target on the stock in a research report on Monday, November 7th. First Analysis upgraded shares of Cambrex Corp. from an “equal weight” rating to an “overweight” rating and set a $54.00 price target on the stock in a research report on Monday, November 7th.
In other Cambrex Corp. news, insider Gregory Sargen sold 22,500 shares of the company’s stock in a transaction on Friday, November 11th. The shares were sold at an average price of $52.02, for a total transaction of $1,170,450.00. Following the sale, the insider now directly owns 27,500 shares of the company’s stock, valued at $1,430,550. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.63% of the company’s stock.
Cambrex Corp. Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.